Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Registration Number
- NCT05693012
- Lead Sponsor
- Qiu Lugui
- Brief Summary
It is an observational, case-control study aimed at early-detection of multiple myeloma and constructing a prognostic model of multiple myeloma. The study will enroll approximately 398 participants including patients with multiple myeloma, patients with benign hematologic disorders and healthy participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 398
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma. 12 months
- Secondary Outcome Measures
Name Time Method The specific cfDNA methylation landscape of multiple myeloma in China 12 months The differently methylated regions(DMRs) between multiple myeloma and healthy/benign controls.
The sensitivity and specificity of a cfDNA methylation-based early detection model for multiple myeloma at different clinical stages. 12 months The performance of a cfDNA methylation-based prognostic model for multiple myeloma. 12 months Treatment response and survival outcomes, measured by ORR, CR, PFS, and OS, in high-risk group and low-risk group of multiple myeloma.
Trial Locations
- Locations (1)
National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
🇨🇳Tianjin, Tianjin, China
National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College🇨🇳Tianjin, Tianjin, ChinaLugui Qiu, MD, Ph.DContact23909172qiulg@ihcams.ac.cn